Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.
Lakshmi NayakNathan StandiferJorg DietrichJennifer L ClarkeGavin P DunnMichael LimTimothy CloughesyHui Kong GanElizabeth FlaggElizabeth GeorgeSarah GaffeyJulia HaydenChristina HolcroftPatrick Y WenMary MacriAndrew J ParkToni RicciardiAileen RyanPaul SchwarzenbergerRalph VenhausMelissa de Los ReyesNicholas M DurhamTodd CreasyRaymond Y HuangThomas KaleyDavid A ReardonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Patients with recurrent glioblastoma have markedly lower baseline levels of multiple circulating immune cell subsets compared with newly diagnosed patients. An early increase in systemic Ki67+CD8+ cells may warrant further evaluation as a potential biomarker of therapeutic benefit among patients with glioblastoma undergoing checkpoint therapy. Dexamethasone decreased immune cell subsets. PD-L1 blockade and combination with standard or reduced dose bevacizumab was ineffective.
Keyphrases
- newly diagnosed
- phase ii study
- induced apoptosis
- peripheral blood
- dna damage
- end stage renal disease
- open label
- low dose
- locally advanced
- chronic kidney disease
- cell cycle
- cell cycle arrest
- squamous cell carcinoma
- stem cells
- cell death
- rectal cancer
- radiation therapy
- bone marrow
- prognostic factors
- endoplasmic reticulum stress
- replacement therapy
- pi k akt
- metastatic colorectal cancer